The Keratoconjunctivitis Sicca (Dry Eye) drugs in development market research report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Keratoconjunctivitis Sicca (Dry Eye). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued products.

GlobalData tracks 174 drugs in development for Keratoconjunctivitis Sicca (Dry Eye) by 146 companies/universities/institutes. The top development phase for Keratoconjunctivitis Sicca (Dry Eye) is preclinical with 66 drugs in that stage. The Keratoconjunctivitis Sicca (Dry Eye) pipeline has 171 drugs in development by companies and three by universities/ institutes. Some of the companies in the Keratoconjunctivitis Sicca (Dry Eye) pipeline products market are: Chongqing Kerun Biopharm R & D, Azura Ophthalmics and Huons.

The key targets in the Keratoconjunctivitis Sicca (Dry Eye) pipeline products market include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16), Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1), and Integrin Alpha L (CD11 Antigen Like Family Member A or Leukocyte Adhesion Glycoprotein LFA 1 Alpha Chain or CD11a or ITGAL).

The key mechanisms of action in the Keratoconjunctivitis Sicca (Dry Eye) pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with 14 drugs in Pre-Registration. The Keratoconjunctivitis Sicca (Dry Eye) pipeline products include 16 routes of administration with the top ROA being Ophthalmic and 16 key molecule types in the Keratoconjunctivitis Sicca (Dry Eye) pipeline products market including Small Molecule, and Synthetic Peptide.

Keratoconjunctivitis Sicca (Dry Eye) overview

Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants.

For a complete picture of Keratoconjunctivitis Sicca (Dry Eye)’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.